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ABSTRACT

Correlates of Antidepressant Medication
Compliance Use Among Depressed Women

by

Pamela Linton, Master of Science
Utah State University, 2001

Major Professor: Dr. Scot Allgood
Department: Family and Human Development

Medication compliance/no ncompliance was examined in context of: severity of
sympto ms; medical side effects; medication education; perceived stigma; and effects on
family/soc ial support system. A null hypothesi s was formulated for each correlate,
stating that those patients who reported a high level of an independent variable (IV)
would not be any more likely to discontinue their medication tban patients who reported a
lew level of an IV. To obtai a data, a medical usage questionnaire and a depressior,
assessment (OQT"-45.2) were used. Statistical significance was not obtained for any of
the hypothesized relationships but trends were cons istent with the established literature.
The impl ication points to the efficacy of relational therapy as a conjunct to the medical
treatment of depression.
(76 pages)
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CHAPTER I
INTRODUCTION

Physicians report that female patients, diagnosed with depression, often
discontinue their antidepressive medications spontaneous ly, translating into prolonged
problems for the women . Noncompliance with the physician's prescription is a problem
because the depression returns and the medication process has to start over again
(Munizza, Tibaldi, Bollini, Pirfo, & Punzo, 1995). Patients may not be aware that
spontaneous discontinuation of antidepressive medication can cause an increase in
depression due to reduction of a therapeutic level of medication (Munizza eta!.).
The severity of depression acts as a cata lyst in medication compliance because of
the associated complications of symptoms (Bhatia & Bhatia, 1997). Because depression
is a major problem in this country, studi es are necessary to understand more about the
nature of depression and medication com pliance (Coyne, 1987; Hirschfeld, 1994).
Depression of an individual also impacts his or her family. Marriage relationships
influence and are influenced by depression (Coyne, 1987). However, tbe side effects of
antidepressant medication may impact the marital relationship if, for exampl e, the woman
is dealing with decreased libido or unwanted weight gain (Jensvold, Plaut, Rojansky,
Crenshaw, & Halbreich, 1996; Shen & Hsu, 1995) or decreased emotional responsi vity.
Thus, the immediate side effects of the medication may be a strong deterrent to
medication compliance.
Research suggests that medication co mpliance is low when the patient receives
inadequate infom1ation about the antidepressant medication from the prescribing doctor

2
and the pharmacist (Crenshaw & Goldberg, 1996). Many physicians and pharmacists
realize that they should take time to educate patients about medication use,
pharmacology, and side effects. Research has shown that there are specific ways that
those topics can be approached with female patients so that maximum benefit can result
(Blechman & Brownell, 1988 ; Crenshaw & Goldberg, 1996; Jensvold et al. , 1996;
Sorvaniemi, Joukamaa, Helen ius, & Salokangas, 1996). Thus , education about the
medication is clearly linked to comp liance; that is, compliance is greater when the patient
is fully informed about the medication.
Some women report to their primary care physicians that husband and family are
concerned about the stigma or the embarrassment of having their wife or mother treated
for depression (L. Eskelson, personal communication, March, 5, 1998; R. Wortham,
personal communication, December l , 1998). [n addition, many women also worry what
others in their larger support system will think of them (M. Gibby, personal
communication , May 7, 1998). To alleviate the concerns patients feel about the stigma of
having depression, they may disco ntinue treatment by discontinuing their medication.
The concern about stigma may be greater than the concern about medication compliance.

Purpose

The purpose of this study was to investigate compliance or noncomp liance
(discontinuation) with antidepressant medication prescription in context of severity of
symptoms, medical side effects, medication education, perceived stigma, and effects on
family/soc ial support system.

3
Conceptual Framework

To investigate compliance or noncompliance with antidepressant medication
prescription in context of selected correlates, an overarching framework of human
behavior must be integrated into the study. By broadening the lens of human behavior,
assumptions can be made within a framework that accounts for behavior. According to
Symbolic Interaction theorists, all meaning comes from interpretations that people attach
to their interactions with one another (LaRossa & Reitzes, 1993). Everyday interactions,
historical events, culture, and societal norms all influence individuals and prompts their
motives and behavior (LaRossa & Reitzes). For some susceptible individuals, negative
meaning attached to certain interactions may res ult in the development of depressive
symptoms. Meaning is also derived concerning motivations to stay in compliance with
prescribed antidepressant medication or to discontinue medication.
Symbolic interactionism (Sl), within the context of general systems theory
(GST), merges two dynamic theories to account for much human behavior. The following
GST constructs (using the terminology of Gregory Bateson, considered the father of
systems theory, and Ludvig von Bertalanffy) del ineate ways we may order our world
(Go ldberg & Go ldberg, 1980; Whi techurch & Constan tine, 1993). Nonsummativity is
another word for synergy, the concept that a system (nations, communities, families,
couples, or an individual) is greater than the sum of its parts (Whitechurch &
Constantine). This concept underlies the belief that compliance or noncomp li ance with
antidepressant medication must be explored not only on an individual level but in light of
interconnections with the family and the social support systems.
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Cybernetics theory suggests the idea that systems are self-regulating (Goldberg &
Goldberg, 1980; Guttman, 1991 ). Self-regulation is accomplished through change within
the system, which occurs through the process of feedback loops (Goldberg & Goldberg;
Guttman). Positive feedback initiates a second order change-- e.g., the individual takes
information and processes it to change from the original meaning that he or she had.
When the feedback results in a negative feedback loop, the individual will use that
information to reinforce previous beliefs (Goldberg & Goldberg; Guttman).
Self-regulation, through the process of feedback loops, is critical to understand in
connection with compliance or noncompliance with medication. Medication education
and perceived stigma (two of the correlates of compliance or noncompliance with
medication) are critically influenced by self-regulation. For a patient to assimilate
medical education, a positive feedback loop may have to be processed to stay in
compliance with medication prescription. In other words, if patient perception of
antidepressant medication does not match the doctor's perception, she must change her
way of thinking to stay in compliance with mediation prescription.
Concerning stigma, if patients continue in a negative feedback loop, they may
reinforce their previous beliefs about st igma. In other words, if a patient believes there is
a stigma attached to antidepressant medication use, she will use that information to
reinforce her belief. As an individual communicates with other systems, all information
is processed through the unique lens of the individual. The "other systems" of concern in
this study are family members, friends, health practitioners, and psychotherapists.
Important parts of communication are the report (actual information) and command

(interpretation) concepts (Guttman , 1991). In any communication one cannot be sure
that the information sent to another is interpreted as it was intended.
Communication about each of the correlates of antidepressant compliance or
noncompliance is vital. For instance, the information an individual processes about
medical side effects and severity of symptoms may result in actions that will either
promote compliance or noncompliance with antidepressant medication. It is necessary to
communicate with all the appropriate systems to attain as much consensus in meaning as
possible (Guttman, 1991). The research focus of this study, compliance or
noncompliance with antidepressant medication in the context of the correlates (severity
of symptoms, medica l side effects, medication education, perceived stigma, and effects
on family/socia l support system) was investigated from the perspective of SI and GST. It
is also important to investigate the communication concerning the con·elates.
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CHAPTER II
REVIEW OF LITERATURE

Although there is no consensus of the definition and cause of depression, there are
recognized correlates to the use of antidepressant medication. Five areas of concern are
connected to the research on antidepressant medication use among women. First, the
severity of the symptoms of depression is a factor that often determines use or nonuse of
medication. Second, medication discontinuance may be tied into the dynamics of a
woman's fam ily and social support system, which are profoundly impacted by her
depression. Third, the negative side effects from use of antidepressant medication vary
widely and may be compounded by other medical problems. Fourth, if the patient does
not have a basic understanding of the chemistry and function of antidepressant
medication, she will not realize the gravity of proper medication use. Finally, the social
stigma that is still attached to depression is such a powerful deterrent to acknowledging
depression that its role as a correlate in antidepressant use cannot be ignored. Thus,
patient cooperation with medication treatment may decrease as risks and si de effects
increase. Depression and corre lates of the use of antidepressant medication are further
discussed in the following review.

Depression

Millon and Everly ( !985) defined depress ion as the decompensation of normal
personality patterns. Nom1al personality patterns are the deeply embedded and broad ly
exhib ited cognitive, affective, and overt individual behavioral traits that are constant over
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time and are difficult to extinguish (Mi llon & Everly). The criteria for a major depressive
episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (4 1h
edition; DSM-IV), are five or more of the following symptoms that have persisted for a
2-week period and must include either symptom# I or #2:
l. Depressed mood most of the day, nearly every day
2. Diminished interest or pleasure in almost all activities nearly every day
3. Significant weight loss or gain or decreased or increased appetite nearly daily
4. Insomnia or hypersomnia nearly every day
5. Psychomotor agitation or retardation nearly every day
6. Fatigue or loss of energy nearly every day
7. Feelings of worthlessness or excessive or inappropriate guil t nearly every day
8. Diminished ability to think or concentrate, or indecisiveness , nearly every day
9. Recurrent thought of death, recurrent suicida l ideation, or suicide attempt or specific
suicide plan
The symptoms of depression must also include a clinically significant distress or
impairment in soc ial , occupational, or other important areas of functioning and the
symptoms cannot be attributed to bereavement, namely, recent loss of a loved one
(American Psychiatric Association , 1994).
A hallmark symptom of depression that may be manifest in all of the above noted
symptoms is cogni tive rigidity, or the tendency to focus in an ali-or-nothing thought
process (Beck, Ward, Mendelson, Mock, & Erbaugh, 196 1). Cognitive rigidity generally
results in distorted thinking, locking thought processes into worst case scenarios-thereby
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reinforcing the previously mentioned symptoms.
Blechman and Brownell ( 1988) noted that several classes of clinical depression
included the following factors: genetic, biological, stage of female reproductive cycle,
and social/psyc hological , which include gender roles and cognitive distortion. Given the
gender specificity of some of these factors, it is not surprising that more women are
diagnosed with depression than men (American Psychiatric Association, 1994; Hansen &
Osborne, 1995; Renzetti & Curran, 1995). Williams, Spitzer, Linzer, Kroenke, & Hahn
( 1995) concluded that (p. 656) "women are much more likely than men to have
depress ive disorders ... [f]urther research is needed to determine why women seem to
suffer disproportionately from symptoms of depression .... " Although more women are
diagnosed with depression than men, the accepted standard for diagnosing symptoms
among both men and women follows the criteria from the DSM-fV (Lesseig, 1996).

Severity of Symptoms

The severity of symptoms can be partially exp ressed by understanding the
complications of depression. When depression is not diagnosed, the client has a greater
chance of developing other symptoms such as medical, substance-abuse, academic, and
work-related problems (Bhatia & Bhatia, 1997). This is significant considering " the ove r
all national economic burden of mood d isorders is approximatel y $44 billion" (Bhatia &
Bhatia, 1997, p. 1683). Personal and econom ic problems associated with depression are
substantial and may be magnified by the comp lex and time-consuming process of
diagnosis and treatment intervention strategies.
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Depression diagnosis must be assessed in the following areas to determine its type
and severity and the most appropriate treatment plans: suicidal ideology, secondary
depression, bipolar depression, psychotic depression, masked depression, seasonal
depressio n, atypical depression, major depression superimposed on dysthymia, treatmentrefractory depression, and adjustment disorder with depressed mood (Bhatia & Bhatia,
1997). A thorough evaluation of the above forms of depression is necessary to prescribe
the optimal therapeutic (menta l and/or medical) intervention.
The process is further complicated as co-occurring conditions may compound the
sevetity of symptoms (Lesseig, 1996). Wesi, Zarin, and Pincus ( 1997) stated that "mood
disorders constituted the most common principal DSM-IV diagnostic category, affecting
53 percent of the patients in this study [and] the majority [also] had significant
psychiatric and general medica l co-occurring condi tions" (p. 79). Results from a study
by Fava eta!. ( 1997) show that "several symptoms characteristic of eating disordered
patients are linked to the severity of depress ive symptoms" (p. 140). Because the scope
of depress ive symptoms and coex isting conditions is serious, proper diagnosis is
necessary to treat the patient efficaciously. It is common practice for a medical
practitioner to monitor patient medications in conjunction with the patient rece iving
psychotherapy (West et a!., 1997). The combination of medication and psychotherapy is
efficacious. Hirschfeld ( 1994) stated that "psychotherapy plays a critical fu nction in the
long-term treatment of depression." Patients with depression, espec ially long-standing or
recurrent depression, often have serious marital, familia l, social, and occupational
problems that have been exacerbated by their illness. In addition, psychotherapy may
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help to improve compliance, whi ch helps to prevent relapse" (p. 68).
As noted, there is a clear case for a thorough evaluation and assessment of
depression. The severity of depress ion may render a person less capable of monitoring
the very medication that would alleviate the problem. If a patient has a diminished ability
to think (one of the criteria for depress ion), he or she may not be ab le to follow through
with taking the prescribed medication. Secondly, co-occurring problems raise other
issues rel ated to compl iance in taking medication. The first concern is misdiagnosis,
when other symptoms are treated whi le depressive symptoms are overlooked. The
depression may lead the person to fee l hopeless and not take the medication to help
reduce related symptoms. The second concern with co-occ urring problems is related to
the cost of multip le medications, whi ch may reduce comp liance.

Antidepressant Medication Side Effects

Medical professional s prescribe antidepressant drugs to com bat depressive
symptoms. The three maj or classes of drugs are the serotonin selecti ve reuptake
inhibitors (SSRis), tricyc lic antidepressants (TCAs), and the monamine oxidase inhibitors
(MAOis). The SSRis are less toxic and have milder side effec ts than the TCAs
(Montano, 1994 ). Li, Hamdy, Sandborn, Chi, and Dye r ( 1996) suggested that patients
taking TCAs and SS Ris can experience " impairment of balance function ... motor
coord ination, fine -motor contro l, postural reflexes, maintaining equilibrium , and reaction
time" (p. 19 1). The MAO! class of antidepressants "can cause sedation [slowing down of
physical and mental functioning], heart palpitations [throbbing of the heart] , di zziness,
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insomnia, sexual dysfunction [normal sexual function disturbed] , tachycardia [racing of
the heart], constipation, agitation, and edema [swelling of tissues] ... and the possibility
of hypertensive crisis [elevation of hypertension]" (Nemeroff, 1994, p. 5). Long ( 1998)
observed that some antidepressant medications, particularly the tricyclics, have disturbing
side effects, such as weight gain and weight loss. Patients using Prozac, Luvox, Paxil,
and Zoloft (SSRl class of antidepressants) exhibit anorexia more often in overweight
patients, and weight gain in patients after chronic use (Bezch1ibnyk-Butler & Jeffries,
1998). Bhatia and Bhatia (1997) reported no weight gain with the use of Prozac, Luvox,
Paxil , and Welbutrin. In the tertiary tricyclic class of antidepressants, amitriptyline
(Elavil) exh ibits a weight gai n (over 6 kg) 30% of the time; the next highest incidence is
with clomipramine (Anafranil), doxepin (Sinequan), and imipram ine (Tofranil),
exhibiting weight gain 10% of the time (Bezchlibnyk-Butler & Jeffries, 1998). The
secondary tricyclics amoxaprine (Asendin) and nortriptyline (Pamelor) show a low
incidence of weight gain (Bhatia & Bhatia, 1997). Weight gain (over 6 kg) reported in
the MAO! class of antidepressants is as follows: phenelzine (Nardi!), 10%, and
tranylcypromine (Pamate), 2% (Bezchlibnyk-Butler & Jeffries, 1998).
Often sexual functioning is affected by medications prescribed for depression
(Crenshaw & Goldberg, 1996) through increased libido (Gartrell, 1986) or decreased
libido (Crenshaw & Goldberg, 1996) with both being potentially problematic. The
antidepressant medications most highl y associated wi th sexual dysfunction are the SSR.Is:
fluoxetine (Prozac), parocetine (Paxil), sertraline (Zoloft), and fluvoxamine (Luvox); the
TCAs: clomipramine (Anafran il), Elavi l, Endep, Norpramin, Pertofrane, Adapin,

12
Sinequan, Tofranil, Aventyl, Pamelor, Vivactil , and Surrnontil; and the MAOis: Marplan,
Nardi! , and Pamate (Aldrich, Cook, & Pedersen, 1996; Lesseig, 1996). Welbutri n
(bupropion), an SSRI, affects sexua l dysfunction least (Aldrich et al. , 1996; Lesseig,
1996). Antidepressant drugs also have been reported to induce other mental disorders
such as rapid cyc ling of mood change (Oppenheim, 1982). Thus, the prob lems with
antidepressant medication can range from mild distress to a life-threatening potential.
"Completed suicide is a major risk in depressive illness" (Iso metsa, Aro,
Henriksson, Heikkinen, & Lo nnqvist, 1994, p. 523). The connection between suicide and
depression is a complex prob lem. If depressive symptoms cannot be diminished, then
suicidal ideation rises (Iso metsa et al., p.78). Presc ribed antidepressants, however, have
the risk of becoming the means fo r attempting su ic ide. When persons in major
depress ion receive medication and become more lucid than they have been in the past,
they may have a greater capacity for suicide ideation or even anempt the act (Slaikeu ,
1990). After starting an antidepressant drug regimen , mental hea lth professionals
recognize the ri sk of the eminent transition from incapaci tating depress ion to increased
functioning that may culminate in a suicide anempt or completion (Slaikeu, 1990). "It is
recommended that the practitioner limit the prescription ofTCAs (tricyclic
antidepressants) to a sublethal dose, particularly early in the course of therapy for
depression, since some patients may be more energized to commit suicide as their
depression begins to lift" (Lesseig, 1996, p. 78).
Pati ent cooperation with medication treatment may decrease as risks and side
effects increase. A patient may have profound discomfo rt from a side effect, namely,
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dizziness, insomnia, sexual dysfunction, tachycardia, constipation, or edema (Nemeroff,
1994), and discontinue the antidepressant medication. The patient may decide to
discontinue the antidepressant medication because of the immediate discomfort it is
causing (Long, 1998). Thus , the antidepressant medication may be discontinued before
its beneficial effects can take place. Because of the risks and side effects associated with
using antidepressant medication, the medical practitioner also acts as a medication
manager, monitoring the effects of the drug and changing dosages and/or drugs as
necessary.

Medication Education

Management of depress ion is a growing concern for medical doctors (Bhatia &
Bhatia, 1997). Many family practice physicians have a strong commitment to patient
education concerning antidepressant medication (Bhatia & Bhatia, 1997; L. Eskelson,
personal commun ication, March 5, 1998; M.Gibby, personal communi cation, May 7,
1998). Patient education about antidepressant medication needs to come from both the
doctor prescribing the medication and the pharmacist. Areas of importance include the
pharmacology, indications, contraindications, warnings, precautions, adverse effects, and
dosage of the medication along with seasonal influences and alternatives to medication
(Long, 1998; Luke, 1998). Knowing the fami ly history of depression and medication use
is helpful because "response [to medication] runs in families" (Lesseig, 1996, p. 76). If
the patient does not have a basic understanding of the chemistry and function of
antidepressant medication, she may not realize the gravity of her recommended
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medication use and may discontinue essen tial treatment.

Perceived Stigma

Stigma is a rea l concern that interferes with clients reporting depression because
they still assoc iate depression with emotional or spiritual weakness (Montano, 1994).
Campbell ( 1996) defined stigma as a label given to people who are mentally disordered,
whereby it justifies di scrimination against them. In a study by the National Alliance for
the Mentally Ill (Gwirtsman, Blehar, McCullough, Kocsis, & Prien, 1997), family
members were asked if they had experienced stigma and most families reported that

stigma had a sign ificant effect on the family member with mental illness and family
functi oni ng. Montano also reported that "nearly 70% of the respondents in a survey sa id
that stigma was attached to admitting mental illness" ( 1994, p. 26).
If a patient feel s he or she is stigmatized, then other emotions may follow such as
shame, gu ilt, anxiety, fear, or anger. Max men and Ward ( 1995) described shame as an
emotion assoc iated with embarrassment, whi le guilt is an emotion associated with
worthl essness. To understand the responses of shame and guilt, Zukerman (1995)
applied desc riptors to them: burdened, self-condemning, disgraced, devalued, fears
rejection/abandonment, failure to attain goals or measure up, and wishes to disappear.
Zukerman proposed the following distinction between guilt and shame: shame is
associated w ith a failure of being and guilt is assoc iated with a failure of doing.
According to Erik Erickson' s theory of development, humans must resolve the conflict of
shame to attain se lf-con tro l, and the conflict of guilt to develop direction and purpose
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(Cole & Cole, 1993). When the depressed individual is experiencing the effects of
stigma and associated emotions, the stress it causes may interfere with the patient's
ability to act with the necessary degree of direction and self-control to stay in compliance
with prescribed antidepressant medication.
Anxiety or fear may be associated with st igma. To understand the responses of
anxiety or fea r, Zukerman ( 1995) applied descriptors to them: adrenaline secretion,
stomach acid production decrease, loss of bladder/ana l sphincter control, nausea, cold
sweats/chills, faintness, chest pain, hyperventilation, difficulty breathing, and the fightor-flight response (a physiological stress or response to fear) which may embody the
preceding responses and more. The Diagnostic and Statistical Manuai of Mental
Disorders (4'" edition) defines phobias as persistent fears associated with high levels of
anxiety (American Psychiatri c Association, 1994). According to Maslow's Hierarchy of
Needs (Zukerman, 1995), safety is one of the basic needs that must be met to facilitate
self-actualization (the abi li ty to meet ones physical and emotional needs). If an
individual is not able to progress toward se lf-actualization, the associated stress may be
over-burdening to the individual, and family/social support system.
It appears that the emotions evoked by stigma may interfere with individual
emotional development, which may create or exacerbate problems within the patient's
family/social support system. When a patient already is feeling the symptoms of
depression, the negative impact it has on the family and social support systems, the side
effects of medication, and the difficulty assimilating the precautions associated with
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medication use, the added anguish of coping with stigma of depression may be more than
the patient can bear.

Effects of Family/Social Support System

Depression is associated with relationship problems. Research suggests that
depressed individuals are often treated in ambivalent ways (sympathetic and hostile) and
find great difficulty or impossibility in recovering without help (Baucom & Epstein,
1990). Research is needed to investigate depression and relationship interaction, but
existing research suggests that the dynamics of relationships are influenced by depression
(Coyne, i 987). Some of the problems associated with depression include the fact that
individuals often fail to find pleasure in life, suffer from energy loss, cry often, have
numerous physical complaints, cannot function optimally, and have suicida l ideation
(Coyne, 1987; Lambert & Burlingame, 1996; Lesseig, 1996).
Because of these problems associated with depression, the family/social support
system is affected negatively. Coyne ( 1987) stated that the entire family of a depressed
person is at considerable risk for negative outcomes. Coyne also stated that the
relationships between depressed persons and their spouses are often conflictual and
overtly hostile. Baucom and Epstein ( 1990) stated that a circular pattern tends to develop
in families of depressed individuals "in which negativity and lack of positive
responsiveness on the depressed spouse's part elicits hostility and withdrawal from the
partner, which in tum elicits anxiety, more depression and demand for reassurance by the
depressed person" (p. 114). Baucom and Epstein ( 1990) further stated that because of the
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circular negative communication pattern, couples may require extensive intervention, but
the depressed individual may be so depressed that he or she is unable or unwilling to
participate in therapy. Fava eta!. ( 1997) reported that the severity of depression may
heighten interoceptive awareness or interpersonal distrust, resulting in a sense of
alienation and reluctance to form close relationships. From the reports of Coyne ( 1987),
Baucom and Epstein ( 1990), and Fava et a!. ( 1990), it appears that depress ion adversely
affects the famil y/social support system.
Research shows that the following factors are associated with depress ion:
biogenetic, family history, family environment, social background, temperament, mood,
interpersonal/cognitive abilities , socia l context, stressors, personal resources, and soc ial
resources (Kupfer & Frank, 1998). Kupfer and Frank discussed recent efforts to develop
assessment of psychosocial and biologica l risk factors associated with depressio n that
may develop a more integrated theory to further explain the impact of depress ion.
Another facto r associated with depression that impacts the fami ly/social support
system is the fact that medical conditions , chronic illnesses, and other disorders often cooccur with depression (Lesseig, 1996; Fava et al., 1997). Chronic illness such as multiple
sc lerosis, certain viruses and cancers, and thyroid and/o r adrenal disorders co-occur with
depress ion (Lesseig, 1996). There is also evidence linking eating disorders to depression
(Fava eta!., 1997). It is clear that for a patient and fam ily dealing with depression and
co-occurring problems, a significant burden exists.
Once treatment (antidepressant medication) begins, the patient and family find
that it takes approximately 4 to 6 weeks fo r the medication to take effect and relieve some
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of the depressive symptoms (Lesseig, 1996). If the medication has to be changed fro m an
SSRl to a MAO! there are washout periods, defined as the time needed between stopping
one drug and beginning the other (Lesseig, 1996). The washout period for switching
from an SSRJ to a MAO! is 2-5 weeks. Thus, the family and patient find that though
treatment has begun, they may still be burdened by the effects of depression for another
2-3 months before some symptom alleviation occurs.
Another disrurbing siruation arises for the family when the late-emerging adverse ·
effects of SSRls occur. The late-emerging adverse effects, namely, anorexia, anxiety,
fatigue, insomnia, and/or sexual dysfunction , can be confusing because the pati ent and
family may think the depression is worsening instead of getting better (Lesseig, 1996).

Summary

The symptoms of depression place a considerable strain on the depressed person
and her relationsh ips. Without support from fami ly, friends, and cohorts, the added
burden of seeking and following through with treatment may be overwhe lming. The
severity of the depression alone may be so great that it interferes with her ability to
comp ly with medication prescription. When the pattern of connection among the
correlates that con tribute to disuse of antidepressant medication is discovered, specific
interventions can be used to support the patient in managing her depression.
The specific null hypotheses for this srudy in volve the five contexrual issues
correlated with medication compliance or noncompliance:
I. Severity of symptoms: Patients who report severe symptoms of depression are
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no more likely to discontinue medication treatment than patients who report mild or
moderate symptoms.
2. Medical side effects: Patients who report adverse medication side effects are
no more likely to spontaneously discontinue medication treatment than patients who do
not experience medication side effects.
3. Medication education: Patients who can express the properties of the
antidepressant medication and their possible side effects are no more likely to continue
medication as prescribed than patients who cannot express the properties and effects of
an antidepressant medication.
4. Perceived stigma: Patients who report a low leve l of stigma are no more likely
to continue antidepressant medications than patients who report a high degree of stigma.
5. Effects on family/soc ial support system: Patients who strongly agree that
depression has had a negative effect on their family/social support systems are no more
likel y to discontinue antidepressant medication use than patients who disagree that
depression has had a negative effect on their family/socia l support systems.

20
CHAPTER ill
METHODS

Design

This is a correlational study of the degree of association between the variab les
being sntd ied. Correlational stud ies examine relationships between variables without
experimenta l manipulation (M iller, 1986). The vari ables in this study (severity of
sympto ms, medical side effects, medication education, perceived stigma, and effects on
family/soc ial support system) were not controlled or manipulated but examined ex post
fac to (after they occurred). A medical usage questionnaire (see Appendix B) was used to
gather data about the variab les. To strengthen the design, a doubl e-b lind study was used,
meaning that the women who answered the questionnaire and the perso ns who
admini stered the questionnaire were not informed about the research quest ions (null
hypotheses).

Samp le

Data were collected from September 1999 to March 2000. It was estimated that
eac h provider would see 30 to 40 female patients with depression during the time of the
study. Women were chosen as the population for this study rather than men and/or
ch ildren because the correlates may vary accordi ng to gender and age. In addition,
studies indicate that depressive epi sodes occur twice as frequently in women as in men
(American Psychiatric Association, 1994).
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The sample of women surveyed consisted of 35 women who had been previously
prescribed antidepressive medication and who came back into the doctor's office for any
reason. The women surveyed were 18 years of age up to age 72, with an average age of
39. On average, respondents had three children, had attended about a year of college,
and had a household income of $46,000 (see Table I).

Table I
Demographic Summarv of the Sample
Catego~

n

Minimum

Maximum

Mean

so

Age

34

18.00

72.00

39.26

L1.87

Number of children

34

.00

7.00

3.00

1.92

Total household income (in 1000s)

28

12.00

120.00

46 .62

27.94

Years of education comeleted

34

12.00

19.00

12.82

3.57

Almost three fourths of the sample were not receiving therapy, but of those that
were, most reported benefitting (see Table 2). Six women noted they would be interested
in receiving information about psychotherapy. The population for this study included the
female patients of one psychiatrist (!2 = 7); four family practice physicians (!2 = 12); and
two certified physician assistants (!2 = 16) from the Cache Valley region, located in both
northern Utah and southern Idaho.

Measurement

The survey included an introductory statement explaining that many women have
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found it difficult to stay on their medications. A medical usage questionnaire was
devised to gather demographic infonnation; symptoms, social support, side effects, and
medication compliance.

Table 2
Sample Resources or Needs Related to the Treatment of Depression
Yes

No
(n)

(n)

Resources/Needs

n

%

Receiving therapy

33

27.30

Therapy/medication are helping

14

85.70 (12)

14.30

(2)

Need infonnation about therapy

28

21.40

(6)

78.60

(22)

(9)

%

72.70 (24)

The Outcome Questionnaire (OQ'm-45.2; Lambert & Burlingame, 1996) is a 45item, self-report questionnaire. The assessment is measured on a summated rating scale
or Likert-type scale, in which the responses to the questions are answered along a
continuum with five possible choices ranging from "never" to "almos t always." Th e
questionnaire assessed three areas: symptom distress, interpersonal relationsh ips, and
social role. The resulting sco res can be more infonnative if the clinical cutoffs are used
rather than using the raw scores. Scores above the cli nica l cutoffs are indicati ve of
diagnosable problems. The symptom distress subscale consists of 25 questions assessing
symptoms of depression, anxiety, and substance abuse. Total scores range from 0- l 00,
with 36 being the clinical cutoff. The interpersonal relationship subscale uses 11
questions to detennine distress in marriage and family relations. Scores range from 0-44,

23
with 15 being the clinical cutoff. Social role distress is a nine-item subscale to determine
problems related to work, friends, and society. Scores range from 0-36, with 12 being the
clinical cutoff. Each questionnaire area was scored separately and then the three scores
were added together for a total score. The cutoff score for the whole measure is 63, with
scores above this representing clinically significant symptoms.
The OQ <m_ 45.2 is a standardized measure with established reliability and
validity. Both the internal consistency and test-retest va lues have high coefficients. The
va lues are reported in each area with the internal cons istency value preceding the testretest reliability value: symptom distress (.92; .78), interpersonal relationships (.74; .80),
social ro le (.70; .82), and an OQ <m_ 45.2 total score (.93; .84; Lambert & Burlingame,
1996).
Concurrent validity was estimated by using the Pearson product-moment
con·elation coefficients (Cohen, 1988) on the total OQ

<m_ 45

score and on individual

domain scores that correspond to segments in ll other tests accepted in the field as being
valid. The criterion measures were all significant beyond the .01 level of confidence
(Lambert & Burlingame, 1996). The counterparts to the OQ <m_ 45.2 and their values (the
first value is the correlation with the symptom distress component and the second value is
for the total OQ <m_ 45.2 value) include the General Symptom Index of the Symptom
Check List- 90-Revised (SCL-90-R) (.61; .78); Beck Depression Inventory (BDI) (.63;
.80]; Taylor Manifest Anxiety Scale (TMA) (.88; .86]; State-Trait Anxiety Inventory
(STAI Y-2) (.65; .80]; Inventory of Interpersonal Problems (liP) (.62 ; .54]; Social
Adjustment Scale (SAS) (.45; .65]; SF-36 Medical Outcome Questionnaire (SF-36) (.80;
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.81]; and the Friedman Well -Being Scale (FW-B) [.77; .81] (Lambert & Burli ngame,
1996).
The concl usion is that the OQ 'm- 45.2 is va lid because the concurrent validity
va lues are significant beyond the .0 l leve l when compared with I 1 other tests accepted as
valid in the fie ld. The internal consistency and test-retest reliability values in each area
are also high, ranging from .70 to .93 (Lambert & Burlingame, 1996). The calcu lated
total reliability score for the OQ ,m_45.2 is .84 (Lambert & Burlingame). The Cro nbach's
alpha fo r the present sample was .95 for symptom distress, .89 for interpersonal
re lations hip, .93 for social ro le, and .94 for the overall measure.
The medical usage questionnaire, consisting of 25 questions, assessed
demographic information, the dependent and independent variab les, and involvement
with psychotherapy. Demographi c information assessed included age, number of
ch ildren , income, education, religios ity, and marital status. Age, number of children,
income, and education were determined by write-in questions to determine a specific
answer rather than a general category. The write-in questions were des igned to increase
vari ability for measurement. Marital status was determined using questions formatted
like those used by the United States Census Bureau for the 2000 census: married ,
divorced, separated, and never been married (U. S. Census Bureau, 1998)
Religiosity was measured to determine the assoc iati on between religios ity and an
objection to taking medication for a psychological condition. Religiosity was measured
using questions from the Intri nsic Religious Motivation Scale (IRMS ; Hoge, 1972).
Hoge deve loped the IRMS as a measure of motivation for religious behavior. The !RMS
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contains I 0 items with a Likert-type scale. Intrinsic religiosity is a strong religious
motivation and extrinsic religiosity is the relative absence of religious motivation (Hoge).
A reliability coefficient of .90 was achieved by Hoge utilizing the Kuder-Richardson
formula 20, and the IRMS also corre lated .8 5 with Feagin's Intrinsic-Extrinsic Scale
(Hoge). The Soderson adaptation of the IRMS was used because of the increased scoring
choices for the purpose of increasing variab ili ty among the scores: strongly agree,
moderately agree, slightly agree, slightly disagree, moderately disagree, and strongly
disagree (Hoge). Each item was assigned a point value and high scores indicated more
intrinsic religious motivation and low scores indicated less intrinsic religious motivation
(1-Ioge).

The fRMS assumes that extrinsic religious motivation ts the relative absence of

intrinsic religious motivation (1-Ioge). Four questions from the IRMS were deemed
appropriate for the survey. The Cronbach 's alpha for the four questions used in the
present samp le was .83, which justifies the appropriateness of the chosen questions.
The next segment of the medical usage questionnaire asked, " Have you
disco ntinued your antidepressant medication on your own?" The yes/no response format
was designed to determine if the patient was being comp liant or noncompliant in the use
of the prescribed medications.
Antidepressant medication side effects were assessed using four L ikert-type
questions wi th fi ve possible responses. The questions asked about four common side
effects associated with sexual functioning and weight variation. The questions were
chosen from in formation in the current li terarure concerning antidepressant medication
(A ldri ch et al., 1996; Bezchlibnyk-Butler & Jeffries, 1998; Crenshaw & Go ldberg, 1996;
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Gartrell , 1986 ; Lesseig, 1996; Nemero ff, 1994; Oppenheim , 1982). [n addition, the five
medical professionals who participated reported the questions had both face and content
validity. lntemal reliability for these questions had an alpha coefficient of .69.
Medication education was assessed with three Likert-type questions w ith five
possible responses. The questions inquired how informed the patient was about the
chemical properties and usage of her medication. The questions were formed from
personal communication and by reading the current literature about medical education
concerning antidepressant medication (Bhatia & Bhatia, 1997; L. Eskelson, personal
commun ication, March, 1998; M. Gibby, personal communication, May, 1998; Lesseig,
1996; Long, 1998; Luke, 1998). The five medical professionais also reported these
questions had face and content validity. The statistical reliability of these quest ions for
the current samp le was a Cronbach's alpha of .82.
To assess the presence of stigma, two six point Likert type questions were asked.
The questions were taken from the current literature o n stigma and depression
(Gwirtsman et al., 1997; Montano, 1994). Patients were asked if they felt there was a
stigma attached to depression and if someone in their family feels there is a stigma
attached to depression. These questions were also reported to have face and content
validity by the medical profess ional s. The internal reliability for these questions was .7 1.
The final two questions were "yes" or "no" questions to assess the presence and
desire for psychotherapy in connection with the patient's depression. Coyne (1987) and
Hirschfeld (1994) acknowledge the beneficial effect of psychotherapy in connection with
depression. Reference materials were left in the offices of the participating medical
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practitioners for the patient who wanted more information from a therapist concerning
her depression.

Procedures

Data collection began by contacting health care practitioners who had prescribed
antidepressive medication to female patients diagnosed with depression. Each
practitioner delineated the methods used to assess depression. The participating
practitioners were interviewed concerning the problem of their female patients
spontaneously discontinuing their med ications. The medical professionals were asked to
describe the treatment cycle for depression and their evaluation of that process. It was
deteim ined that some women start medication, spontaneously discontinue medication,
and then return to the physician's office and begin treatment again (L. Eskelson, personal
communication, March 5, 1998; M. Gibby, personal commun ication, May, 1998).
A packet containing a brief explanatory paragraph to the patient, the OQ <m - 45.2,
and a medication usage questionnaire was delivered to the practitioners for their
approval. It was delivered with a cover letter exp laining the research statement: "We are
conducting a study to find more about how women use antidepressant medication
prescribed by their physic ian and what influences these decisions." Office personnel who
distributed and received the surveys were oriented by the practitioner and trained by the
researcher. The packet was then distributed, by the nurse, to patients who the practitioner
determined would participate. This was conducted in the doctor's treatment room to
promote professionalism and create a convenient private place to answer the questions.
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A consent waiver and confidentiality fonn and two questionnaires were used to
collect data. The questionnaires were the OQ

•m_45.2, and a medication usage

questiollnaire. As patients presented at the physician's office for treatment, a packet
containing the fonns was given to clients who had previously been prescribed
antidep ressant medication. This was the standard method of administering the
questionnaires. Questions involving the independent variables indicated patient concern
in each of the several areas.
The questionnaire was designed to be completed in fifteen minutes. The survey
served a two-fold purpose: (I) to provide data for this research and (2) and to provide an
indication of patient thought process. The answers were computer coded for statistical
analysis. The results were shared with the physicians for use with their patients.

Ethical Considerations

An Institutional Review Board (IRB) review was conducted prior to surveys
being distributed. All universities that conduct research with human subjects are
mandated by federal guidelines to have an IRB (Leary, 1995). The purpose of the IRB
review is to assure protection of human subjects associated with research projects
(Leary). A written proposal of the research was subm itted to and approved by the IRB
(see Appendix A).
The survey given to the women initially began with an infonned consent in the
introductory paragraph explaining the research. The infonned consent included risks,
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benefits, confidentiality, and patient rights (see Appendix B). The surveys were
anonymous to secure confidentiality of answers and the participants cou ld decline
to take the survey.
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CHAPTER IV

RESULTS

In this chapter the degree of association is reported between the independent
variables and co mpliance with an ti depressant medication as stated in each null
hypothesis. The dependent variable (DV) is compliance/noncompliance with medication
prescription as stated. There were 19 patients who were in compliance with medication
and 15 were not. There is so me variance in the number of noncompliant/comp liant
patients because of missing data for the independent variables. The independent
variables (IV) are interval level measu res: severity of symptoms, medical siue effects,
medication education, perceived stigma, and effects on family/social support system.
The appropriate analyses for this study was the l test. A l test was chosen to
determ ine whether mean scores differed for those who discontinued medication,
compared with those who remained in comp liance. The assumptions for the sing lesample 1 test are (a) there was o ne random sample of interval sco res ; (b) the raw sco re
population formed a normal distribution for which the means is the appropriate measure
of central tendency; and (c) the standard deviation of the population (patients in
medication compl iance and those in noncompliance) was estimated to be the sa me
(Heiman, 1996). The dependent variab le (DV) was a dichotomous measure
(comp liance/noncompliance of medication) and the independent variable (IV) is an
interval level measure. The 1 test compares means and from those means, test statistics
demonstrate the abil ity of the data to meet the criteria to show stati stical sign ificance.
ln addition to the l test, it was appropriate to go one step further to report the
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effect size. Effect size is a measure of the strength of a relation. Vogt ( 1993, p. 79)
stated that
tests of the null hypothesis only allow you to conclude that a relation is
sign ificantly larger than zero, but they do not tell you by how much.
Effect size measures do. Thus the effect size is an estimate of the degree
to wh ich a phenomenon is present in a population and/or the extent to
which the null hypothesis is false.
Effect size was calculated by subtracting the mean of patients who discontinued
medication usage from the mean of patients who conti nued with medication usage. The
difference wo.s then divided by the standard deviation of those who continued medication
usage (Durlak, 1995). The scores were then recorded in absolute values. The
transformation into effect sizes reflects the relati ve magnitude of effect in a common
term, standard deviations, allowing for meaningful comparisons from one variable to the
next.

In this study, an effect s ize of l.O would mean that the medication compliance

score differed one standard deviation higher or lower than the medication noncompliance
score. Durlak reported that "effect sizes of around 0.20 have a sma ll magnitude of effect,
those around 0.50 have a medium magnitude of effect, and those around 0.80 have a high
magnitude of effect" (p. 328). However, in some areas of research, mean effects of 0.50
may be co nsidered large (Vogt, 1993).
To test hypothesis 1 (severity of symptoms: patients who report severe symptoms
of depression are no more like ly to discontinue medication treatment than patients who
report mild o r moderate symptoms) the symptom distress subscale of the OQ •m-45.2 was
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used as an indicator of symptom severity. Medication compliance/noncompliance was
the dependent variable . The! test for this hypothesis did not reach levels for statistical
significance (see Table 3).
Patients who di scontinued medication reported more severe symptoms than those
who continued medication. It should be noted that the mean scores in the present sample
are above the clinical cutoff parameters representing symptom distress for both groups.
The effect s ize in the present srudy was .58, which represents a medium to large
assoc iation.

Table 3
Patients in Noncompliance/Compliance with Antidepressant Med ication Paired with
Severitv of Symptoms

Patients n = 30

Noncompliant patients
(Medication
discontinuance)
M
SD

Comp li ant patients
(Medication
continuance)
M
SD

Severity of sym ptoms

46.77

39.32

17.8 1

12.80

1.38

g

ES

. 19

.58

While the two groups (those in medication compliance, and those in
noncompliance) were not statistically different, the effect sizes do indicate a stro ng
association in the expected direction. The trend is that patients who were noncompliant
with their antidepressant medication prescription had a greater degree of sympto m
distress. While the trend is noticeable, the differences were not statisticall y different, and
hence the null hypothesis must be accepted.
One possibility for the distress scores being so high is that the underlying
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problems are not being treated by the antidepressant medication. To assess this, a
frequencies table was done to compare medication noncompliance/compliance and
receiving some type of psychotherapy (see Table 4). Then was too low for statistical
analysis. The low numbers of women receiving therapy were evenly spread between the
medicatio n noncompliant and compliant groups.

Table 4
Frequencies Comparing Medication Noncompliance/Compliance with Receiving Therapy
Noncompliance
(medication
discontinuance)

Groups

Compliance
(medication
continuance)

5

4

No therapy

13

10

Total

18

14

Receiving therapy

To test hypothesis 2 (medical side effects: patients who report medication side
effects are no more likely to spontaneously di scontinue medication treatment than
patients who do not experience the most common medication side effects) four questions
concerning side effects were used. The first two questions read, " ! have experienced a
10% weight gain since taking my antidepressant," and"! have experienced a 10% weight
loss since taking my antidepressant medication," and were answered yes or no. With a
dichotomous independent variab le, the most appropriate analysis for both weight loss and
gain was chi square. The frequencies and analyses are found in Tables 5 and 6. Ph i, a
measure of association, was also calculated.
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Table 5
Frequencies and Chi-Square Analysis Comoaring Medication Noncompliance/
Compliance with Weight Gain
Noncompliant patients
(medication
discontinuance)
n (%)

Category
Weight gain

Yes

No
Note . Chi square= 1.11

Compliant patients
(medication
continuance)
n
(%)

8 (47%)

9

(53%)

4 (29%)
Q = .29 phi = .19

10

(71%)

Table 6
Frequencies and Chi-Square Analysis Comparing Medication Noncompliance/
Compliance with Weight Loss
Noncompliant patients
(medication
discontinuance)
Category
Weight loss

Yes
No

Note . Chi square= 1.56

Q= .21

n
3

(%)
(60%)

7

(30%)
phi= .24

Compliant patients
(medication
continuance)
2

(%)
(40%)

16

(70%)

n

The other questions, "I have problems with my own low sexual interest or desire
that seems to be related to antidepressant medication" and "I have problems with sexual
functioning that seems to be related to antidepressant medication," were posed as Likert
questions and were tested with! tests. The results for both questions are found in
Table 7. The DV was medication compliance/noncompliance (see Table 7).
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Table 7
Patients in Noncompliance/Compliance with Antidepressant Medication Paired with
Medication Side Effects

Patients
Loss of sexual
interes t (!L= 34)

Noncompliant patients
(med ication
discontinuance)
so
M

Compliant patients
(medication
continuance)
M
so

3.00

2.04

3.53

2.04

Loss of sexua l
function (n = 34)

3.23

2.24

3.47

2.06

Q

ES

.72

.48

.11

.70

.75

.11

An examination of the data shows that reducing the data to mean scores loses
valuable information. There appears to be a clear curvilinear re lationship with the
majority of the women being fairly equally represented at both ends of the responses. A
frequency table shows the raw scores for the women in the sample (see Table 8).
The null hypothesis stated that patients who reported medication side effects
would be no more likely to spontaneously discontinue medication treatment than patients

Table 8
Freguencv Rate of Patient ResQonse to Sexual Side Effects
Likert choices

Category
Loss of sexual interest
Loss of sexua l function

2

3

4

5

10

4

3

3

5

9

6

3

Strongly agree

5

6
Strongly disagree
9
10
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who were not informed about medication side effects. Since none of the analyses were
statistically significant, the null hypothesis must be accepted
To test hypothesis 3 (medication education: patients who can express the
properties of the antidepressant medication and their possible side effects are no more
likely to continue medication as prescribed than patients who cannot express the
properties and effects of an antidepressant medication), three questions concerning the IV
(medication education) were used: "When you were prescribed antidepressant
medication, how well did your physician explain the properties of the medication and
what you cou ld expect?"; " When you filled your prescription for antidepressant
medication, how well did your pharmacist exp lain the medication and what you could
expect?"; and "Did your physician or pharmacist inform you abo ut the side effects of
you r medication?" A low score meant the patient received more information. The DV
was medication co mpliance/noncompliance (see Table 9).
An examination of the mean scores shows that the women believed their

physicians explained the properties of the medi cations. The women also thought the ir
pharmacists exp lained the medications but not as well as their physicians. The
explanation on the possible side effects was made clear for the women by both the
physicians and pharmaci sts.
The null hypothesis stated that patients who could identi fy the properties of the
antidepressant medication and their possible side effects would not be more likely to
continue medication as prescribed than patients who could not express the properties and
effects of an antidepressant med ication. None of the statistical analyses were statistically
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Tabl e 9
Patients in Noncompliance/Compl iance with Antidepressant Medication Paired with
Medication Education
Noncompliant patients
(medication
discontinuance)

Compliant patients
(medicatio n
continuance)

Questions

M

so

M

so

1

Explanation of
properties by
physician (n_= 30)

1.75

.75

1.94

.80

Exp lanation of
properties by
pharmac ist (!! = 29)

2.58

1.3 1

2.64

Explanatio n of
side effects (n = 3 1)

2.31

l.l l

2.22

Q

ES

-.67

.51

.24

1. 00

-.15

.88

-.05

l.l 7

.21

.84

.07

s ignificant. Si nce the results were not statistically sign ificant, the null hypothes is was
accepted.
To test hypothesis 4 (perceived stigma: patients who repo rt a low degree of
stigma are no more likely to di scontinue antidepressant medications than pati ents who
report a high degree of stigma) , medication comp liance/noncompliance was used as the
dependent variable: "Have you discontinued your antidepressant medication? The IV
was measured three ways. The first component of stigma was a fa ith measure used to
indicate the patient's perception of faith, and indi rectly her perception of stigma
concerning her relationship with deity. The second component of the stigma measure
was patient report that she feels stigma is attac hed to depression. The final stigma
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measure was the patient' s report that the family feels there is stigma attac hed to
depression.
The patients who discontinued medication reported virtua ll y the same level of
faith as those who continued medication. Both groups reported high degrees of faith,
scoring over three fourths of the available responses. Thus in the first component, the
women did not report feeling stigmatized by their faith, which is consistent with the null
hypothesis (see Table 10). The second and third components of stigma (self-perception
of stigma and perception of stigma by others) were also tested and were not statistically
different (see Table 10).
The means in all three analyses were not statistica lly different. An examination of
the raw data revealed some interesting trends for stigma from se lf and others. Over one

Table 10
.Patients in Noncompliance/Compliance with Antidepressant Medication Paired wi th
Perceived Stigma
Compliant patients
(medication
continuance)
M
SD

Stigma

Noncompliant pati ents
(medication
discontinuance)
M
SD

Reli gion stigma

19.38

4.77

19.79

5.25

-.22

.82

.07

Stigma of self
(!!._= 32)

3.46

2.18

3.18

1.74

4.00

.69

.13

Stigma from others
(n = 33)

2.38

1.56

3.17

1.86

-1.24 .23

.42

ES

C!:! = 33)
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Table II
Pati ent 's Antidepressant Medication Usage and the Association with Self- Perception of

Categories
Strongly agree

Noncompliant pati ents
(medication
discontinuance)

5

Compliant patients
(medication
co ntinuance)
3

7

Moderately agree
Slightly agree

2

Sl ightl y disagree

2

Moderately disagree

0

Stron gly disagree

3
3

half of all the women reported feeling moderately or strongly stigmatized. For those
who were medication compliant, one third reported not feeling stigmatized (see Tablell ).
There was a clear bimodal trend in the women's report of fee ling stigmati zed by
others. One half of the women reported feeling strongly or moderately stigmatized by
others. Over a third reported strong or moderate disagreement that they fe lt stigmatized
by others (see Table 12).

In relation to the null hypothesis (patients who report a low degree of stigma are
no more likely to discontinue medication treatment than patients w ho report a high
degree of stigma) there were not statistically significant differences. The trend was
inconsistent with the nul l hypothesis, but because the values did not reac h statistical
significance, the null hypothesis must be retained.
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Tabl e 12
Pati ent's Antidepressant Medication Usage and the Association with
Other ' s Perception of Stigma

Categories
Strongly agree

Noncompliant patients
(medication
discontinuance)

Compliant patients
(medication
continuance)

3

3

Moderately agree

4

5

Slightly agree

0

2

Slightly disagree

0

2

Moderate) y disagree

2

3

Strongly disagree

4

2

To test hypothesis 5 (effects on family/soc ial support system: Patients who
stro ngly agreed that depress ion had a negative effect on their fam il y/social support
systems are no more likely to discontinue antidepressant medication use than patients
who disagree that depression has had a negative effect on their family/social support
systems). This analysis was done with l tests. There were no statistically significant
differences between the medication compliant and noncompliant groups in their family or
social support scores (see Table 13).
Patients who discontinued their medication had scores over the cutoff level in
both the area of interpersonal relationship and social role. Those who continued their
medication had scores below the cutoff level in interpersonal relationship and social role.
The effect size for interpersonal relationship (.57) is considered a medium magnitude of
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Table 13
Patients in Noncompliance/Compliance with Antidepressant Medication Paired w ith
Effects on Family/Social Support System
Noncompliant
patients
(medication
discontinuance)
(n = 32)
Category
Interpersonal relationship

M

SO

17.23

7.25

Compliant
patients
(medication
continuance}
M
so
13.58
6.37

Social role

12.15

7.23

1121

3.71

t
\51

p
.14

ES
.57

.49

.67

.26

effect, which indicates that there is a relationship between the IV and the OV .
The effect size for soc ial rol e (.26) is considered a small magnitude of effect, but
still indi cates a relationship between the IV and OV. Since the groups were not
statistica lly different, the null hypothesis must be retained.

42
CHAPTER V

DISCUSSION

This chapter consists of several parts. First, the null hypotheses are discussed in
the order previously presented. The discussion centers on what the results mean as well
as tying each hypothesis to the existing literature. In addition, the d iscussion addresses
the impli cations this study has for the practice of marriage and family therapy.
Limitations of the study are considered, and recommendations are made for future
research.
The first hypothesis, addressing severity of symptoms, was posed as a null
hypothesis: patients who report severe symptoms of depression are no more likely to
discontinue medication treatment than patients who report mild or moderate symptoms.
The null hypothesis was accepted because the stati stical testing did not reach a level of
significance. However, the trend is in the direction found in the literature. An
examination of the mean scores for both groups shows that patients reported high levels
of symptoms, whether they were medication compliant or not. Because both groups
reported sym ptom distress levels above the cutoff level for the OQ '"' - 45.2, this finding is
only partially consistent with the literature . The expected trend for patients in comp liance
with medication would be a subclinical level of symptom distress.
The severity of symptoms can be partially expressed by understanding the
complications of depression. When depression is underrated, the client has a greater
chance of developing other problems, namely, medical, sustance-abuse, academic, and
work related, all of which may reduce medication compliance (Bhatia & Bhatia, 1997).
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West eta!. (1997) stated that a majority of the patients "had significant psychiatric and
general medical co-occurring conditions; 20 percent of the patients had at least three
DSM-fV Axis I mental disorders" (p. 79). Thus it may be that if the symptoms of
depress ion are great and other problems develop, the chance for medication comp li ance
is low. However, according to the OQ <m_ 45.2, the women in this study were still in the
clinicall y sign ificant range of di stress, even though many were in medication comp li ance.
There are at least three possible explanations for distress and medication comp li ance.
The firs t is that individual medicati ons may not be at a therapeutic dosage and therefore
not effecti ve. It may also be possible that the prescribed medications do not work fo r
some women. So me patients require psychotherapy in conjunction with medication to
stay in medication compliance (Hi rschfeld, 1994). West eta!. (1997) noted that it is a
common practice to couple antidepressant medication treatment with psychotherapy.
Further, Hirschfe ld stated that it is not only efficacious but critical to include
psychotherapy in the treatment of depression. With this recommendation availab le in the
literature, it was surprising that just over a quarter of the women were receiving any type
of therapy. It is not known how many women tried therapy or how successful they felt
their treatment was. This trend speaks to the need for the doctors and therapists to work
together dea ling with depressed cli ents.
The second null hypothesis concerning medical side effects was stated thus:
patients who report medication side effects are no more likely to spontaneously
discontinue medication treatment than patients who do not experience medication side
effects. The side effects included in the survey (sexual functioning , sexual interest,
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weight loss, and weight gain) did not show a statistically significant relationsh ip between
them and medication compliance. An exam ination of the data shows that 55% of the
women experienced a 10% weight gain. In addition a small number reported a 10%
weight loss . There was a slight trend in the side effects related to sex. Women who were
not comp liant in takin g their medications reported more of a concern that their sexua l
functioning was negative ly affected by the medications. None of these trends were
statistically signi fi cant. However, Dr. Eskelson (personal communication, March 5,
1998) bas reported that few women report side effects (because of an assumption that
side effects must be endured) when asked how they are responding to the medication.
Embarrassment concerning sexual side effects may also be a deterrent to reporting
effects . The frequencies of the women 's responses for sexual side effects were
interesting. The majority of the women strongly agreed or disagreed that the medications
affected their sexual desire or functioning. This response set is somewhat unusual for a
Likert-type question, indicating the women had clear opinions or experiences. A lmost
half of the women strongly or moderately agreed that the medi cations caused sex ual
problems, which is consistent with the literature. It may be that the other half of the
women, who strongly or moderately disagreed, were on medications that did not cause
those same sexua l side effects.
The patient may decide to discontinue the antidepressant medication because of
the immediate discomfort it is caus ing (Long, 1998). Thus, the antidepressant medication
may be discontinued before its beneficial effects can take place. It may be that the degree
of distress caused by the medication in conjuncti on with the degree of distress the patient
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has from the depression put some patients at more risk for medication noncompliance. If
patients have profound discomfort from side effects, they often discontinue the
antidepressant medication (Nemeroff, 1994). The trend of this study is generally
consistent with the existing literature; patients who reported a greater degree of distress
also tended to discontinue their antidepressant medication.
The third null hypothesis focused on medication education: patients who were
informed about the properties of the antidepressant medication and their possible side
effects are no more likely to continue medication as prescribed than patients who were
not informed. The analyses showed no differences in compliance when compared with
explanation of the medication properties or side effects. The means reveal that the
women felt their doctors gave very detailed information about the medications. The
explanation of drug properties by the pharmaci sts was rated as detailed. The explanation
of the possib le side effects from both the doctors and pharmacists was also described as
detailed. This is consistent with the doctors ' report. A ll of the health practitioners in this
study reported that they include information on how the medications work as well as
possib le side effects in their patient education (D. Beckstead, personal communication,
April, 1998; L. Eskelson, personal comm un ication, March, 1998; M. Gibby, personal
communication, May, 1998; P. Jones, personal communication, November, 1998; J.
Kirby, personal communication, December, 1998; K . Wade, personal commun icati on,
November, 1998; R. Wortham, personal communication, November, l998). Whi le the
doctors all reported providing patient information, an examinati on of the raw data
showed that two women reported their doctors gave no explanation. Eight women
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reported their pharmacists did not explain the medication properties. Six women reported
neither their doctor nor pharmacist explained the side effects. It is poss ible that the stress
of depression interfered with patient ability to assimilate the physician/patient education
process. It is also possible that the medical professionals assumed the patients knew
more than they actually did.
Another component of patient education is that it is helpful to know the family
history of the patient because type of patient response runs in families (Lesseig, 1996).
Thus it is important to know if the patient has a family history of experiencing side
effects or habitual medication compliance or noncompliance. Dr. Gibby (personal
communication, May, 1998) and Dr. Eskelson (personal communication, March, 1998)
also reported that the response of the family to antidepressant medication can have a
greater effect on the patient staying in compliance than the education given by the doctor.
This is understandable when viewed through the lens of general systems theory.
Feedback loops are a major factor in GST (Guttman, 1991). If the family 's response is
more important to the patient than the practitioner's response, that results in a positive
feedback loop, or a reinforcing of the origin ai belief. If the practitioner's information is
more valuable to the patient than the family's perception, a negative feedback loop
occurs. The negative feedback loop is a deviation from the original belief, or it
represents change. In summary, the majority of the women felt informed about the
properties and side effects of the medication. It is notable, however, that a sizab le
number of women reported having little or no information.
The fourth null hypothesis focused on perceived stigma: patients who report a
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low degree of stigma are no more likely to contin ue antidepressant medications than
patients who report a high degree of stigma. Three areas of stigma were assessed. For
the first area, questions concerning faith were asked to determine if patients feel that God
does not approve of them. This was an measure of intrins ic religious motivation, not
extrinsic motivation. Thus the deeply held persor.al convictions about relationship with
deity were addressed. The results showed the compliant and noncompliant group means
were very sim ilar and statisticall y nonsignificant. Stigma from God was measured in an
indirect manner. It is possible that respondents were responding to religious
commitments and not perceived stigma.
Additional questions were asked to determine self-stigmatization and
stigmati zation by others. Neither of these analyses was statistically significant. An
exami nation of the raw data revealed some interesting trends. In terms of feeling
stigmatized by se lf, the majority of the respondents felt moderately or strongly
stigmati zed. Compl iant patients had a bimodal distribution, with one third of the
respondents reporting little or no se lf-stigma. Given the trends in the data, it is likely that
given a larger samp le size, the differences would have been more noticeable. The data on
feeling stigmatized by others formed an interesting contrast to self-stigma. One half of
the respondents moderately or strongly agreed they felt stigmatized by others. For the
noncompliant group, there was a group of virtually the same size who moderately to
strongly disagreed about feeling stigmatized. This group who did not feel stigmatized is
somewhat puzzling. They are not consistent with the literature, which would seem to
make them more likely to take their medication.
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Montano ( 1994) reported that stigma is associated wi th depression. Most
fam ili es (with a depressed member) report that there is a stigma attached to depression
(Montano). [n addition, education about depression helps to alleviate stigma. It may be
that families in smaller communities have less access to stigma-allaying education. Guilt
and shame (the emotions that may follow stigma) are feelings reported by depressed
persons. Because guilt and shame respo nses are debilitating traits (Zukerman, 1995),
humans must resolve guilt and shame to develop direction and purpose in li fe (Co le &
Cole, 1993). It may have been that a group of these women had resolved these issues and
therefore felt no stigma.
The fifth null hypothesis was: patients who strongly agree that depress ion has
had a negati ve effect on their family/social support systems are no more likely to
disco ntinue antidepressant medication use than patients who di sagree that depression has
had a negative effect on the ir famil y/socia l support systems. Whi le stati stical
signifi cance was not obtained, the trend shows that women who discontinued their
medication reported more symptoms in their close relationships and social support than
those women who contmued their medtcation. Women who discontinued their
medication also scored above the cutoff leve l on the social role and interpersonal
relationships components of the OQ tm_ 45.2. The scores above the cutoff level indicate
significant levels of problems in these areas. This is consistent with the previous
hypotheses that the women were feeling stigmatized. It is reasonable to assume that
women who did not take their medication experienced increased negative effects in their
fami ly and socia l support systems.
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The results of this study are not statistically different, but the differences are
clinically significant (Jacobson & Fol lette, 1984). Women who did not continue their
medication were above the clinical cutoffs for both interpersonal and social role
subscales . The cutoff scores can be helpful as they distinguish between distressed and
nondistressed people in the areas of measurement. Thus the women in the medication
noncompliant group fall in the clinically distressed range, while the women in the
medication compliant group wou ld be classified as nondistressed.
The literature clearly indicates that depression is associated with relationship
problems. This may occur because depressed people are often treated in ambivalent
(sympathetic and hostile) ways (Baucom & Epstein, 1990). The problem is increased by
the fact that depressed persons find it difficu lt or impossible to recover without help
(Baucom & Epstein). The depressed person needs support to recover but Coyne ( 1987)
has reported that depressed persons and their spo uses are often conflictual and overtly
hostile . Baucom and Epstein ( 1990) added that a circular pattern tends to deve lop in
these families: the negativity of the depressed person elicits hostility/withdrawal from
the partner, which causes more depression in the depressed member. Thi s process may
be accentuated if the women do not take their medications.

In summary, the women in the sample are distressed whether they continue their
medications or not. In addition, most experience side effects and feel stigmatized. The
general concl usion is that results were consistent with the literature even though results
were not statisticall y significant.
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Implications for Therapy

Although levels of statistical significance were not reached with the null
hypotheses, trends from the data present useful information for the practice of marriage
and family therapy. The following are implications for the practice of marriage and
family therapy: First, the literarure suggests that there is a beneficial effect of
psychotherapy in connection with depression (Coyne, 1987; Hirschfeld, 1994); thus the
combinati on of medication and psychotherapy is efficac ious. The data from this srudy
show that only a small num ber of the women were receivi ng psychotherapy. This is
critical , as Hirschfeld ( 1994, p. 337) has stated, "Psychotherapy plays a critical function in
the long-term treatment of depression. Patients with depression, espec ially long-standing
or recurrent depression, often have seri ous marita l, familial, social, and occupational
problems that have been exacerbated by their illness." In addition, Law and Crane (2000)
reported that people receiving marriage and family therapy services are less likely to need
health care services. Thus the first recommendation is that therapists and doctors need to
be more collaborative when treating depressed cl ients.
Second ly, the research also acknowledges that compliance with antidepressant
medication is a problem and suggests that the combination of psychotherapy and
medication is efficaciou s. An obvious benefit is that the therapi st can reinforce the
educati on the doctors and pharmac ists provi de.
Thi s srudy showed that patients have and react to severe symptoms of depression,
side effects , stigma, and negati ve effects on family/socia l support system, despite
medication education. It also shows that the patients who were most depressed had the

51
lowest degree of compliance with medication. The therapists can encourage medication
compliance while helping reduce the impact on the family.
A third implication is related to the assessment of depression. This assessment
can be expanded by increasing the interaction between practitioner and therapist. The
majority of the practitioners in thi s study want to know what more can be done to help
treat depression. David Beckstead, M. D., a referring physician, believes that most
patients are not clinically depressed but are suffering from being overwhelmed by life,
which is not resolved by antidepressant medi ca tion (personal communication, April 7,
1998). Receivi ng help for life issues falls within the realm of therapy, which can be an
excellent reso urce for not only the health professional but also the patient.
From a medical standpoint, depression is treated in the following ways: The
psychiatri st who participated in th is study, James Kirby, M.D., evaluates his clients and
prescribes medication for depression and the associated side effects. Dr. Kirby continues
to monitor patie nt medication in conjunction with a referral to psychotherapy. His
approach combines medication and therapy. The physicians and physician assistants
report they are being updated regularly concerning the pharmaceutical aspects of
depress ion. They report a sizeable patient load with depression concerns. Their time is
spent diagnosing, prescribing, and monitoring medication for depression and they can
benefit from assistance with the concerns psychotherapy addresses. Psychotherapy is
designed to address stigma, negative effects on family/support systems, and coping
strategies for depression and its side effects. The psychotherapy mode l advocates
integrating the following elements within three areas: (l) basic endowment: biogenetic,
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family history, family environment, social background; (2) developmental Processes:
social context, interpersonal/cognitive, mood, temperament; and (3) mediators: stressors,
personal resources, social resources (Kupfer & Frank, 1998). The ideal alliance is a
partnership between physician and therapist. The specific psychotherapy treatment
approach suggested by the American Psychiatric Association (2000) is to evaluate for
severiry of depression to determine any need for medication. With or without medication
psychotherapy is recommended for symptom relief.

Limitations

The major limitations of this study are its small and unrepresentative sample.
Medical practitioners agreed to gather data for this study to help find ways to alleviate
the medication compliance problem. The practitioners and office staff were generous in
this offer and anticipated knowing the results of this srudy. However, it was difficult for
the medical office staff to gather data as it appears that they were already functioning at
maximum capaciry. Each office was given 25 questionnaires and it was anticipated that
150 rerurned questionnaires could be obtained. Over a 6-month period oniy 36
questionnaires were rerumed.
It also should be noted that volunteers who completed questionnaires may be
different from the general population suffering from depression. It is possible that
women who participated were so distressed they utilized their health care options more
than other women, and hence the sample was skewed in a negative or more distressed
direction. Conversely, participants might have been less distressed than the general

53
population. The extent of sample bias cannot be determined and thus it cannot be figured
into the study results.
The biggest problems with low n are that the sample is not big enough to examine
larger patterns and to fac ili tate effective statistica l testing. Thus the low n precluded use
of more advanced statistical methods to examine how the different factors worked
together.

Recommendations

In retrospect, it appears that more data may have been co ll ected if the researcher
had

~ol l ec ted

the data in each medical office. The time spent by the researcher

monitoring the data collection over a period of 6 months could have been better spent in
co ncentrated periods gatheri ng data in eac h office.
There is always a concern with measurement validity. In this case the
questionnaire may not be a true reflection of the participant. It may be that the
participants do not interpret questions consistently because o f interpretation variations or
misunderstandings. It may be better to have a trained data collector administer the
questionnaire.
In summary, the purpose of this study was to investigate medication compliance
or noncompliance in the context of the five variables (severity of symptoms, medical side
effects, medication education , percei ved st igma, and effects on family/social support
system) to add to the body of knowledge concerning depression. Within this purpose was
the researcher's goa l to raise awareness of the efficacy of using marita l and family
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therapy as a conjunct to the medical treatment of depression. Within the limited scope of
thi s study, it appears interest and awareness concerning therapy were increased among
the medical practitioners and staff who participated.
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prescribed by their physician, and what things inflw:ncc that decision. This study may benefit
medicaVpsychologicallcnowlcdgo and othcn now and in tho future.
A member of your physician'• office staff has explained this study to you and answered
your questions. If you havo other qucotions or research-related problems, you may reach
Professor Scot M Allgood a.t (43$) 1S3-S89S. Puticipation in = c h is entirely voluntary.
You may refuse to puticipate or withd.taw at any tiine without any·conscquoncc.
Your results will be~ confidential according to federal and state laws. There will be
no way to link your name with your questionnaire. Only the investigaton will have ..:ccs to the
data, and it will be ~ in a locked filo cabinet when picked up from your doctor.
The ln•titutional Review Board (IRB) for the protection of human subjccu at Utah State
University has reviewed and approved this = c h project. Your rctum of this questionnaire
to porticipate · this project.
implico that you UDd=tand the above information and

-::;~~~~

Scot M. Allgood, Pb.D:=;ll! Investigator

'
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Medication Usage Questionnaire
Many women have trouble

s~aying

on their antidepressant medications. Please complete the follow ing

survey to help us understand why. These two surveys (Medication usage Questionnaire and OQ-45) are
co nfidenti al so do not put yo ur name on them. T hey will no t be atta ch ed to yo ur pa ti ent fil e. Certain
issues have been included because they are tho ught to influence how people use their medication. Please

co mpl ete t he fo llow in g items by fillin g in the blank or writin g th e a nswe r.
I. Your age: _ _
2. N umber of children ever born:

3. Total annual household income:$ _ _ _
Please circle a nswer s th a t ma ke the mos t se nse, or a r e th e mo st tru e fo r yo u.
4. Education: years

com~leted

(high school = 12) _ _ _ _ _ _ _ _ _ _ _ __

5. Your current marita l status:

Married

Divorced

Separated

Never been married

6 . Have you had any problems with finances o r medical insurance since you were diagnosed
with depress ion?

Yes

No

7. Aie you currently seeing a psychologist or therapist for your depression ?

Yes

No

8. If you are seeing a psychologist or therapist, is the combination of medi cation and therapy
hel ping you dea l with yo ur depress ion related concerns?

Yes

No

9. If you are nor receiving therapy for your depression, would you like information on available
resources ?

Yes

No
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10. [have experienced a 10% weight gain since taking my antidepressant.

Yes

No

II. I have experienced a I 0% weight loss since taking my antidepressant.

Yes

No

12. How many times a week do you take your antidepressant medication?
Zero

One

Two

Three

Four

Five

Six

Seven

t3. When you don't take your antidepressant medication, what is the reason?
Forget

Cost of refill prescription

Side effects

Other (please _ _ __ _ __ _

14. Have you discon tinued your an tidepressant medication on your own?

Yes

No

Please explain - - -- -- - - - - -- - - - -

15 . How did your doctor prescribe your medication to be taken?

Please e x p l a i n - - - - - - - - - - - - - - - - - - - - - - - - - - - - 16. Have you had follow-up appointments with your doctor for your an tidepressant medication?

Yes

No

17. ffyou are not taking your antidepressant medication seven days/week, how are you taking it?

6 days/week

5 days/week

4 days/week

3 days/week

2 days/week

I day/wk

As needed

Other_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

18. When yo u were prescribed antidepressan t med ication, how well did yo ur physicia n ex pl ain the
properties of the medication and what yo u could expect?

Very detailed

Detailed

Not detailed

No explanation

I don't remember
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19. When you filled your prescription for an tidepressant medica ti on, how well did your pharmacist

explain the medication and wha t you could expect?
Very detailed

Deta iled

No t detailed

No explanation

I don't remember

20. Did your physician or pharmacist inform you about the side effects of your medication?
Very detailed

Detailed

No t detailed

No explanation

I don't remember

21. When you filled your prescription for antidepressant medication, how thoroughly did yo u read the
written material about side effects?
Read thoroughly

Read pretty well

Read a little

Did nor read

I don't remember

For eac h statement there are six (6) possible responses: Strongly agree (I); Modera tely agree (2);
Slightly ai,'Tee (3); Sl ightly disagree (4); Moderately disagree (5); and Strongly di sagree (6).

Please circle answers that make the most sense, or are most tru e for yo u.
4

22. I have problems with my own low sexual interest or desire that
seems to be related to antidepressant medication .

4

23. I have problems with sexual functioning that seems to
be related to antidepressant medication.

4

24. Someone in my family feels there is a stigma attached to
depression.

4

25 . I feel there is a stigma attached to depression.

4

26. My depression has had a negative effect on my family and/or
others.

27. I am satisfied with my marriage?
4

28. I am satisfied with my family?

4

29. My faith involves all of my life.
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30. One should seek Divine guidance when making every important
decision.
4

6

3 1. In my life, I experience the presence of the Divine.

32. My faith sometimes restricts my actions.
4

33. Although I am a religious person, I refu se to let religious

considerations influence my everyday affairs.
34. My religious beliefs under lay my whole approach to life.
35. From yo ur experience what could providers (therapists, doctors, or pharmacists) do that would help
people deal with depre ssive sympto ms? (Respond in the space below)

